New Apps For AI in mRNA With Anima Biotech's Yochi Slonim

Business Of Biotech

We love to hear from our listeners. Send us a message.

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim's not in software development anymore. Not for the software industry, anyway. He's now leveraging his tech chops to develop something with far more potential impact: drugs. On this epsiode of the Business of Biotech, we'll learn about his foray into biopharmaceuticals with Anima Biotech, a company he’s been building for the past ten years and which boasts pipeline partnerships with heavyweights Abbvie, Takeda, and Lilly.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Chapter

1. Tech Entrepreneur's Biotech Venture (00:00:00)

2. Transition Into Biotech and AI Value (00:11:08)

3. AI Imaging and Disease Diagnosis (00:27:58)

4. AI Drug Discovery Platform and Applications (00:33:21)

5. Drug Development Technology and Pipeline Integration (00:39:23)

6. Anima Biotech's Unique AI Approach (00:50:07)